On August 28, 2018 Endocyte, Inc. (Nasdaq:ECYT), a biopharmaceutical company developing targeted therapeutics for personalized cancer treatment, reported that data from the Company’s chimeric antigen receptor T-cell (CAR T) adaptor molecule (CAM) platform will be presented at the CAR-TCR Summit 2018 being held from Sept. 4th – 7th, 2018 in Boston, MA (Press release, Endocyte, AUG 28, 2018, View Source [SID1234529171]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Key Presentations and Symposia:
Chris Leamon, Ph.D., vice president of research at Endocyte, will lead a deep-dive workshop on the Company’s CAM-based therapies and their potential to induce an immune response while mitigating or preventing severe cytokine release syndrome.

Title: Bi-specific Adaptor Controlled CAR-T Cell Therapy for Solid and Liquid Tumors
When: Tuesday, Sept. 4, 2018 from 12:00 p.m. – 2:00 p.m. ET
Session Title: Deep Dive Discussion Day: CAR-TCR Discovery Track
Location: Cityview 1 Room (Seaport Hotel & World Trade Center)

Endocyte will also present a poster with new preclinical data from its CAM-based therapy platform.

Poster #: 15
Title: Bispecific Adaptor Molecule Controlled Folate Receptor CAR-T Cell Immunotherapy: In-Vitro Activity and T-cell Exhaustion Studies
When: Thursday, Sept. 6, 2018 from 8:00 a.m. – 9:15 a.m. ET
Session Title: Scientific Poster Session
Location: Commonwealth Hall Salon C, Harbor Level (Seaport Hotel & World Trade Center)

Endocyte will also present two posters containing previously-presented preclinical data from its CAM-based therapy platform.

Poster #: 4
Title: Adaptor Controlled CAR-T Cell Immunotherapy for Treatment of Folate Receptor-Alpha/Beta Positive Solid and Liquid Tumors
When: Thursday, Sept. 6, 2018 from 8:00 a.m. – 9:15 a.m. ET
Session Title: Scientific Poster Session
Location: Commonwealth Hall Salon C, Harbor Level (Seaport Hotel & World Trade Center)

Poster #: 5
Title: Regulation of CAR-T Cell Therapy in Real-Time Using Bispecific Small Molecule Adaptors in Monospecific Competitors
When: Thursday, Sept. 6, 2018 from 8:00 a.m. – 9:15 a.m. ET
Session Title: Scientific Poster Session
Location: Commonwealth Hall Salon C, Harbor Level (Seaport Hotel & World Trade Center)

Website Information:
Endocyte routinely posts important information intended for investors on its website, www.endocyte.com, in the "Investors & News" section. Endocyte uses this website as a means of disclosing material information in legal compliance with its disclosure obligations under Regulation FD. Accordingly, investors should monitor the "Investors & News" section of Endocyte’s website, in addition to following the company’s press releases, SEC filings, public conference calls, presentations and webcasts. The information contained on, or that may be accessed through, the Endocyte website is not incorporated by reference into, and is not a part of, this document.